Core Insights - Cancer remains a significant global public health challenge, with the WHO reporting 10 million deaths in 2020, accounting for 1 in 6 deaths globally. Without urgent action, cancer deaths could exceed 18 million by 2050 [1][2] - China has emerged as a key player in cancer research, with a record number of studies presented at major international oncology conferences, indicating its growing influence in the field [1][2] - The introduction of 114 new drugs in the 2025 National Basic Medical Insurance Directory, including 36 cancer drugs, expands treatment options for cancer patients [2] Group 1: Cancer Statistics and Projections - The global burden of cancer is expected to rise, with new cases projected to reach 28.4 million by 2040, a 47% increase from 19.3 million in 2020 [2] - The concept of "5-year survival rate" may evolve to "10-year survival rate," with predictions suggesting a 95% survival rate by 2040 and the potential for cancer to be managed as a chronic disease by 2050 [5] Group 2: Factors Influencing Cancer Development - Five main factors contributing to cancer include external triggers, infection-related factors, hormonal/receptor imbalances, lifestyle-related factors, and psychological/immune-related triggers [3] - The essence of cancer is a disruption in the body's regulatory mechanisms, leading to uncontrolled cell proliferation [3] Group 3: Innovations and Future Directions - Advances in technology, including digital communication, genomics, and artificial intelligence, are expected to enhance cancer survival rates and improve access to quality healthcare [4][7] - The establishment of new cancer classification standards and a focus on integrated treatment approaches are anticipated to transform cancer management and clinical outcomes [4] Group 4: Challenges in Cancer Treatment - The transition from fragmented to integrated treatment poses challenges, including the need for updated knowledge among healthcare professionals and the development of innovative diagnostic and treatment technologies [6][8] - Early diagnosis is critical for improving treatment success rates, with AI playing a role in enhancing the identification of high-risk populations [6] Group 5: Immunotherapy Growth - Immunotherapy has emerged as a significant growth area in cancer treatment, with a projected global market size of $84.9 billion by 2030, driven by advancements in CAR-T, TCR-T, and NK cell therapies [7] - Despite its potential, challenges remain in biomarker selection, toxicity management, and cost control, with breakthroughs expected within the next 25 years [7][8]

Core Points - The current national medical insurance directory includes over 230 types of anti-cancer drugs [1] - These drugs cover more than 20 common types of cancer, including lung cancer, breast cancer, and stomach cancer [1] - The directory encompasses chemotherapy drugs, targeted therapy drugs, and immunotherapy drugs [1]